PAD4 catalyses the conversion of peptidylarginine into peptidylcitrulline. Overexpression of PAD4 and the peptidylcitrulline products have been reported in various diseases including rheumatoid arthritis and cancers. GSK199 is the first PAD4 selective reversible inhibitor discovered. The impact of GSK199 binding on PAD4 stability and flexibility, h